Abstract
Background: Design of isoform-specific inhibitors is a major challenge in the new therapeutic agents development.
Methods: The article describes the development of a robust selectivity for CA XII QSAR and 3DQSAR models of 40 benzenesulfonamide derivatives bearing pyrimidine moieties using PHASE module of Schrödinger for 3D-QSAR or E-DRAGON and R software for 2D-QSAR. Two QSAR protocols were explored: traditional (affinity) and selectivity (affinity ratio) based. Results: A total of 25 2D and 3D-QSAR models were developed using a training set of 30 compounds using the two protocols for 6 CA isoforms. A new ad hoc descriptor T(OH..Cl) was created targeting CA XII affinity. Satisfactory results were obtained in terms of model quality expressed statistically as F, R2 and R2 ADJ. Developed models were analyzed using different statistical validation techniques, both by using the Leave One Out (LOO) criterion, and by applying a model on a test set. The Applicability Domains of the 2D-QSAR models were determined. Two PHASE (affinity and selectivity) 3D-QSAR models were rationalized by manual docking of the ligands into the X-ray crystal structures. The affinity and selectivity based protocols were compared. Conclusion: This study provides insights for designing sulfonamide compounds with a better isoform selectivity.Keywords: 3D-QSAR, benzensulfonamide, carbonic anhydrase, drug design, E-DRAGON, phase, QSAR, specificity.
Graphical Abstract
Current Computer-Aided Drug Design
Title:Predicting Isoform-specific Binding Selectivities of Benzensulfonamides Using QSAR and 3D-QSAR
Volume: 13 Issue: 1
Author(s): Vytautas Raskevicius and Visvaldas Kairys
Affiliation:
Keywords: 3D-QSAR, benzensulfonamide, carbonic anhydrase, drug design, E-DRAGON, phase, QSAR, specificity.
Abstract: Background: Design of isoform-specific inhibitors is a major challenge in the new therapeutic agents development.
Methods: The article describes the development of a robust selectivity for CA XII QSAR and 3DQSAR models of 40 benzenesulfonamide derivatives bearing pyrimidine moieties using PHASE module of Schrödinger for 3D-QSAR or E-DRAGON and R software for 2D-QSAR. Two QSAR protocols were explored: traditional (affinity) and selectivity (affinity ratio) based. Results: A total of 25 2D and 3D-QSAR models were developed using a training set of 30 compounds using the two protocols for 6 CA isoforms. A new ad hoc descriptor T(OH..Cl) was created targeting CA XII affinity. Satisfactory results were obtained in terms of model quality expressed statistically as F, R2 and R2 ADJ. Developed models were analyzed using different statistical validation techniques, both by using the Leave One Out (LOO) criterion, and by applying a model on a test set. The Applicability Domains of the 2D-QSAR models were determined. Two PHASE (affinity and selectivity) 3D-QSAR models were rationalized by manual docking of the ligands into the X-ray crystal structures. The affinity and selectivity based protocols were compared. Conclusion: This study provides insights for designing sulfonamide compounds with a better isoform selectivity.Export Options
About this article
Cite this article as:
Raskevicius Vytautas and Kairys Visvaldas, Predicting Isoform-specific Binding Selectivities of Benzensulfonamides Using QSAR and 3D-QSAR, Current Computer-Aided Drug Design 2017; 13 (1) . https://dx.doi.org/10.2174/1573409912666161129153820
DOI https://dx.doi.org/10.2174/1573409912666161129153820 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers